Time to response and survival in hypomethylating agent-treated acute myeloid leukemia-Reference-Cited by-同舟云学术

Time to response and survival in hypomethylating agent-treated acute myeloid leukemia

Published:2017-08-25 Issue:4 Volume:59 Page:1012-1015
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Boddu Prajwal¹^ORCID,Kantarjian Hagop¹,Garcia-Manero Guillermo¹,Ravandi Farhad¹,Jabbour Elias¹,Borthakur Gautam¹^ORCID,Daver Naval¹,Pemmaraju Naveen¹,Pierce Sherry¹,Cortes Jorge¹,Kadia Tapan M.¹

Affiliation:

1. Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1365857

Reference16 articles.

1. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation.

2. Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B

3. Decitabine improves patient outcomes in myelodysplastic syndromes

4. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

5. Acute Myeloid Leukemia After Myelodysplastic Syndrome and Failure of Therapy With Hypomethylating Agents: An Emerging Entity With a Poor Prognosis

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1;Blood;2022-12-15

2. A review of FDA-approved acute myeloid leukemia therapies beyond ‘7 + 3’;Expert Review of Hematology;2021-01-19

3. Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use;Critical Reviews in Oncology/Hematology;2019-08